PHAR
HealthcarePharming Group N.V. · Biotechnology · $890M
What is Pharming Group N.V.?
Pharming Group N.V. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet medical needs. Headquartered in Leiden, the Netherlands, it operates across the United States, Europe, and international markets.
Pharming generates revenue primarily through its lead product, Ruconest, a recombinant human C1 esterase inhibitor approved for acute hereditary angioedema. Beyond its commercial product, the company advances a pipeline targeting conditions such as pre-eclampsia, acute kidney injury, activated PI3K delta syndrome, and enzyme replacement therapies. Collaborations with Novartis and Orchard Therapeutics further expand its research and development reach.
Pharming Group is headquartered in Leiden, the Netherlands.
- Ruconest — recombinant C1 esterase inhibitor for hereditary angioedema
- Leniolisib — PI3K delta inhibitor for activated PI3K delta syndrome
- rhC1INH pipeline — investigational therapy for pre-eclampsia and acute kidney injury
- OTL-105 — gene therapy collaboration with Orchard Therapeutics for hereditary angioedema
Is PHAR a Good Stock to Buy?
UQS Score rates PHAR as Good overall, reflecting a balanced profile with notable strengths and areas that warrant closer attention.
The Growth and Risk pillars stand out as relative strengths, suggesting the company is expanding its commercial and pipeline footprint while managing downside factors reasonably well for a small-cap biopharma. Valuation sits at a Neutral level, neither a clear bargain nor obviously stretched.
The Quality pillar registers as Weak, which is common among development-stage rare disease companies still scaling their commercial operations. Moat is rated Neutral, reflecting the competitive dynamics of the orphan drug space.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PHAR pay dividends?
No — Pharming Group N.V. does not currently pay a dividend.
Pharming Group does not currently pay a dividend. For a small-cap biopharmaceutical company with an active pipeline, this is typical — available capital is directed toward clinical development, regulatory milestones, and commercial expansion rather than shareholder distributions.
When does PHAR report earnings?
Pharming Group reports earnings on a quarterly cadence, consistent with standard practice for internationally listed biopharmaceutical companies.
Revenue trends are shaped by Ruconest sales performance and pipeline progress. Investors typically watch for updates on leniolisib commercialization and collaboration milestones alongside top-line results.
For the most recent quarter's results and guidance, visit Pharming Group's official investor relations page.
PHAR Price History
+40.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Pharming Group N.V.?
Based on Pharming Group N.V.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
PHAR Long-term Outlook
The Good Growth pillar suggests Pharming is on a credible expansion path, driven by its approved product and a maturing pipeline. The Good Risk rating indicates the company is navigating clinical and commercial uncertainties at a level appropriate for its stage. However, the Weak Quality pillar is a reminder that profitability and capital efficiency remain areas to monitor as the business scales.
Growth drivers
- Continued Ruconest commercial uptake in the US and European markets
- Potential leniolisib label expansion and new rare disease indications
- Pipeline milestones from Novartis and Orchard Therapeutics collaborations
Key risks
- Clinical trial setbacks in the development pipeline
- Competitive pressure from other orphan drug developers
- Execution risk as the company scales commercial operations from a small-cap base
PHAR vs Peers
Pharming operates in a competitive rare disease and specialty biopharmaceutical landscape alongside several development-stage peers.
AbCellera focuses on antibody discovery technology and platform-based partnerships rather than direct rare disease drug commercialization.
Precigen pursues synthetic biology and gene circuit technologies across oncology and infectious disease, distinct from Pharming's protein replacement approach.
EyePoint concentrates on sustained-release drug delivery for serious eye diseases, occupying a different therapeutic niche within specialty pharma.
Frequently Asked Questions
What does Pharming Group do?
Pharming Group N.V. develops and commercializes protein replacement therapies and precision medicines for rare diseases. Its lead approved product, Ruconest, treats acute hereditary angioedema. The company also has a pipeline addressing conditions such as activated PI3K delta syndrome, pre-eclampsia, and enzyme deficiency disorders.
Does PHAR pay dividends?
Pharming Group does not currently pay a dividend. The company reinvests available capital into clinical development and commercial expansion of its rare disease portfolio, which is standard practice for small-cap biopharmaceutical companies at this stage.
When does PHAR report earnings?
Pharming Group reports on a quarterly cadence. Exact upcoming dates are best confirmed directly on the company's investor relations page, as our data source does not cover scheduled earnings dates.
Is PHAR a good stock to buy?
UQS Score rates PHAR as Good overall. Strengths in the Growth and Risk pillars are balanced against a Weak Quality reading and Neutral Moat. Whether it fits your portfolio depends on your risk tolerance and investment horizon. The full pillar breakdown is available to Pro members.
Is PHAR overvalued?
PHAR's Valuation pillar is rated Neutral, suggesting the market is pricing the stock in line with its fundamentals rather than at a clear premium or discount. Investors seeking a deeper view can access the complete valuation analysis through a UQS Pro account.
How does PHAR compare to its competitors?
Pharming's focus on protein replacement therapies and hereditary angioedema sets it apart from peers like AbCellera, Precigen, and EyePoint, which operate in antibody discovery, synthetic biology, and ocular drug delivery respectively. UQS Score provides side-by-side pillar comparisons for Pro members.
What is PHAR's market cap bracket?
Pharming Group is classified as a small-cap company. This places it in a segment where growth potential can be meaningful but liquidity and volatility risks tend to be higher than for large- or mega-cap peers in the healthcare sector.
Who founded Pharming Group?
Pharming Group has roots in the Netherlands biopharmaceutical industry. Detailed founding history, including key individuals involved in the company's establishment, is publicly available through the company's official corporate history and investor relations materials.
Is PHAR a long-term quality indicator?
As a long-term quality indicator, PHAR's Good UQS Score reflects genuine pipeline progress and manageable risk, tempered by a Weak Quality pillar that signals the company is still building the financial durability typical of established rare disease franchises. Long-term conviction depends on pipeline execution.
What is the main competitive advantage of Pharming Group?
Pharming's primary competitive position stems from its approved rare disease product, Ruconest, which holds regulatory designations in a niche therapeutic area with limited competition. Its collaborations with Novartis and Orchard Therapeutics also extend its pipeline reach beyond what it could develop independently.
Unlock Full PHAR Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score pillar breakdown across Quality, Growth, Moat, Risk, and Valuation
- ✓Access full financial metrics and trend data for Pharming Group
- ✓Compare PHAR side-by-side against rare disease and specialty pharma peers
- ✓Screen for similar small-cap healthcare stocks using UQS preset filters
- ✓Get the complete analyst-grade view available exclusively to Pro members
Pro Analysis
PHAR — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 48.9 | 40.5 | 40.0 | 66.8 | 52.4 | 50.7 | 0.0 |
| May 13, 2026 | 48.9 | 40.5 | 40.0 | 66.8 | 52.4 | 50.3 | -0.8 |
| May 7, 2026 | 49.7 | 30.8 | 40.0 | 66.4 | 76.8 | 48.1 | +0.1 |
| May 4, 2026 | 49.6 | 30.8 | 40.0 | 66.4 | 76.8 | 47.6 | -1.5 |
| May 3, 2026 | 51.1 | 30.8 | 40.0 | 72.1 | 76.8 | 49.6 | 0.0 |
| Apr 26, 2026 | 51.1 | 30.8 | 40.0 | 72.1 | 76.8 | 49.9 | +0.1 |
| Apr 19, 2026 | 51.0 | 30.8 | 40.0 | 72.1 | 76.8 | 49.1 | -0.1 |
| Apr 18, 2026 | 51.1 | 30.8 | 40.0 | 72.1 | 76.8 | 49.6 | -1.8 |
| Apr 15, 2026 | 52.9 | 30.8 | 40.0 | 72.1 | 76.8 | 62.0 | +0.6 |
| Apr 14, 2026 | 52.3 | 30.8 | 40.0 | 71.5 | 76.8 | 58.4 | +0.1 |
PHAR — Pillar Breakdown
Quality
— 40.5/100 (25%)Pharming Group N.V. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 66.8/100 (20%)Pharming Group N.V. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 52.4/100 (15%)Pharming Group N.V. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 50.7/100 (15%)Pharming Group N.V. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 40/100 (25%)Pharming Group N.V. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PHAR.
Score Composition
Financial Data
More Stock Analysis
How is the PHAR UQS Score Calculated?
The UQS (Unified Quality Score) for Pharming Group N.V. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Pharming Group N.V.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Pharming Group N.V. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.